On Tuesday, Protagonist Therapeutics Inc (NASDAQ: PTGX) opened higher 3.70% from the last session ,before settling in for the closing price of $28.09. Price fluctuations for PTGX have ranged from $13.72 to $33.34 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 2462.45%. Company’s average yearly earnings per share was noted 194.96% at the time writing. With a float of $54.80 million, this company’s outstanding shares have now reached $57.71 million.
Let’s determine the extent of company efficiency that accounts for 112 employees.
Protagonist Therapeutics Inc (PTGX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Protagonist Therapeutics Inc is 5.96%, while institutional ownership is 95.65%. The most recent insider transaction that took place on Apr 01 ’24, was worth 707,750. In this transaction President and CEO of this company sold 25,000 shares at a rate of $28.31, taking the stock ownership to the 549,590 shares. Before that another transaction happened on Mar 01 ’24, when Company’s President and CEO sold 30,000 for $31.62, making the entire transaction worth $948,600. This insider now owns 574,590 shares in total.
Protagonist Therapeutics Inc (PTGX) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/30/2023, the company posted $0.44 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -$0.03) by $0.47. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 194.96% per share during the next fiscal year.
Protagonist Therapeutics Inc (NASDAQ: PTGX) Trading Performance Indicators
Check out the current performance indicators for Protagonist Therapeutics Inc (PTGX). In the past quarter, the stock posted a quick ratio of 16.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 28.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.48, a number that is poised to hit 1.19 in the next quarter and is forecasted to reach -0.81 in one year’s time.
Technical Analysis of Protagonist Therapeutics Inc (PTGX)
Looking closely at Protagonist Therapeutics Inc (NASDAQ: PTGX), its last 5-days average volume was 0.61 million, which is a drop from its year-to-date volume of 0.73 million. As of the previous 9 days, the stock’s Stochastic %D was 63.26%. Additionally, its Average True Range was 1.14.
During the past 100 days, Protagonist Therapeutics Inc’s (PTGX) raw stochastic average was set at 76.30%, which indicates a significant decrease from 78.65% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 24.70% in the past 14 days, which was lower than the 53.69% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $28.39, while its 200-day Moving Average is $21.75. However, in the short run, Protagonist Therapeutics Inc’s stock first resistance to watch stands at $29.58. Second resistance stands at $30.03. The third major resistance level sits at $30.85. If the price goes on to break the first support level at $28.31, it is likely to go to the next support level at $27.49. Now, if the price goes above the second support level, the third support stands at $27.04.
Protagonist Therapeutics Inc (NASDAQ: PTGX) Key Stats
There are currently 58,275K shares outstanding in the company with a market cap of 1.70 billion. Presently, the company’s annual sales total 60,000 K according to its annual income of -78,960 K. Last quarter, the company’s sales amounted to 60,000 K and its income totaled 27,340 K.
